FGF20 and Parkinson's disease: No evidence of association or pathogenicity via α-synuclein expression

✍ Scribed by Christian Wider; Justus C. Dachsel; Alexandra I. Soto; Michael G. Heckman; Nancy N. Diehl; Mei Yue; Sarah Lincoln; Jan O. Aasly; Kristoffer Haugarvoll; John Q. Trojanowski; Spiridon Papapetropoulos; Deborah Mash; Alex Rajput; Ali H. Rajput; J. Mark Gibson; Timothy Lynch; Dennis W. Dickson; Ryan J. Uitti; Zbigniew K. Wszolek; Matthew J. Farrer; Owen A. Ross

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 905 KB
• Volume: 24
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.22442

✦ Synopsis

Abstract

Genetic variation in fibroblast growth factor 20 (FGF20) has been associated with risk of Parkinson's disease (PD). Functional evidence suggested the T allele of one SNP, rs12720208 C/T, altered PD risk by increasing FGF20 and α‐synuclein protein levels. Herein we report our association study of FGF20 and PD risk in four patient‐control series (total: 1,262 patients and 1,881 controls), and measurements of FGF20 and α‐synuclein protein levels in brain samples (nine patients). We found no evidence of association between FGF20 variability and PD risk, and no relationship between the rs12720208 genotype, FGF20 and α‐synuclein protein levels. © 2009 Movement Disorder Society